Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 18/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 8/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 8/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 7/20 | 0.47 |
| ▸ | RARA | P10276 | 2/20 | 0.43 |
| ▸ | RARB | P10826 | 2/20 | 0.43 |
| ▸ | RARG | P13631 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852574 | 1.00 | PDK1 (0.48) | PDK1PDK2PDK4HSP90AA1PDK3 | |
| SCHEMBL22097796 | 0.86 | PDK1 (0.45) | PDK1PDK2PDK4HSP90AA1PDK3 | |
| SCHEMBL22529589 | 0.81 | PDK1 (0.50) | PDK1PDK2PDK4HSP90AA1PDK3 | |
| SCHEMBL22097644 | 0.77 | PDK1 (0.47) | PDK1PDK2PDK4HSP90AA1PDK3 | |
| SCHEMBL12813119 | 0.77 | AXL (0.49) | PDK1PDK2PDK4PDK3 | |
| SCHEMBL25551749 | 0.77 | KMO (0.63) | — | |
| SCHEMBL30036709 | 0.77 | KMO (0.63) | — | |
| SCHEMBL4540379 | 0.76 | ALDH1A1 (0.55) | — | |
| SCHEMBL31592748 | 0.76 | BTK (0.45) | PDK1PDK2PDK4HSP90AA1PDK3 | |
| SCHEMBL22097954 | 0.75 | NPC1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | PDK1 170/4885PDK2 418/4885PDK4 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.